While not accepting the claims of R-Tech Ueno, the arbitral award said the supply agreement among R-Tech Ueno, Takeda and Sucampo executed in 2004 regarding the exclusive supply of Amitiza capsules shall continue to be in effect.
The arbitration requires R-Tech Ueno to continue supply Amitiza capsules to Takeda based on the supply agreement.
R-Tech Ueno will announce its business forecast for the fiscal year ending March 2013 after consideration of the arbitration result.
R-Tech Ueno is a bio venture company established in September 1989 for the purpose of R&D and marketing of drugs, Sucampo Pharmaceuticals is a company focused on the discovery and development of proprietary drugs based on prostones.